MAIA Biotechnology, Inc. (MAIA)

NYSEAMERICAN: MAIA · IEX Real-Time Price · USD
1.360
-0.010 (-0.73%)
Feb 27, 2024, 4:00 PM EST - Market closed
-0.73%
Market Cap 23.27M
Revenue (ttm) n/a
Net Income (ttm) -17.66M
Shares Out 13.63M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 129,029
Open 1.360
Previous Close 1.370
Day's Range 1.310 - 1.420
52-Week Range 0.820 - 4.730
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 22, 2024

About MAIA

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2022
Employees 18
Stock Exchange NYSEAMERICAN
Ticker Symbol MAIA
Full Company Profile

Financial Performance

Financial Statements

News

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...

18 hours ago - GlobeNewsWire

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...

5 days ago - GlobeNewsWire

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer.

20 days ago - Business Wire

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds.

4 weeks ago - Business Wire

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024.

5 weeks ago - Business Wire

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024.

7 weeks ago - Business Wire

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer.

2 months ago - Business Wire

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering.

3 months ago - Business Wire

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., wit...

3 months ago - Accesswire

MAIA Biotechnology Announces $4 Million Registered Direct Offering

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $4 Million Registered Direct Offering.

3 months ago - Business Wire

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

CHICAGO--(BUSINESS WIRE)--FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma.

3 months ago - Business Wire

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO.

4 months ago - Business Wire

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments. CHICAGO, IL / ACCESSWIRE / October 31, 2023 / MAIA Biotec...

4 months ago - Accesswire

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO.

4 months ago - Business Wire

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces 100% Disease Control in 2nd Line NSCLC Demonstrating Impressive Positive Preliminary Efficacy for Ongoing Phase 2 Trial.

4 months ago - Business Wire

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at ESMO Congress 2023.

4 months ago - Business Wire

MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy

CHICAGO, IL / ACCESSWIRE / October 17, 2023 / Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children. Radiotherapy, the curr...

4 months ago - Accesswire

MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society's International Biochemistry Congress 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at International Biochemistry Congress 2023.

4 months ago - Business Wire

MAIA Biotechnology Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer.

4 months ago - Business Wire

MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients.

5 months ago - Business Wire

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas.

5 months ago - Business Wire

MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of NSCLC.

5 months ago - Business Wire

MAIA Biotechnology Announces Share Repurchase Program

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Repurchase Program.

5 months ago - Business Wire

MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

7 months ago - Business Wire

MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment.

8 months ago - Business Wire